Weight loss and treatment patterns in a real‐world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland ( ADDRESS study)
Authors' conclusion
Although reimbursement criteria may be difficult to achieve, particularly the additional weight loss of 5% from Week 16 to Month 10, a clinically relevant overall weight loss from baseline to Month 10 was shown in most individuals with obesity or overweight who received liraglutide 3.0 mg.
Study context
- Population
- Adults with obesity (BMI ≥30 kg/m²) or overweight (BMI >27 to <30 kg/m²) receiving liraglutide 3.0 mg in routine clinical practice in Switzerlandfull analysis set
- Participants
- 258 adults
- Exposure
- Reimbursed vs Non-reimbursed
- Reimbursedn = 195
- Non-reimbursedn = 63
- Outcome
- Proportions in the reimbursed cohort achieving predefined weight loss targets: ≥5% (lower BMI subgroup, 28 to <35 kg/m² with weight-related comorbidities) or ≥7% (higher BMI subgroup, ≥35 kg/m²) at Week 16, and an additional ≥5% from Week 16 at Month 10 (Swiss reimbursement criteria)
- Follow-up
- Week 16 and Month 10
Methodological detailsnon-comparative, multicentre, exposure cohort, real-world
- Non-comparative
- Multicentre
- Exposure cohort
- Real-world
Main finding
As reported in the abstract
Weight loss targets achieved (reimbursed cohort) · Week 16
Reimbursed
71.3%
139 of 195
- Additional 5% weight loss at Month 10 among those meeting Week-16 criteria
- 43.2%
Observational data: associations, not effects.
Further findings
Relative weight loss from baseline to Month 10
- Mean (SD) relative weight loss in 162 individuals with Month 10 data
- −12.4% (6.4%)
Original publication
Weight loss and treatment patterns in a real‐world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland ( ADDRESS study). Diabetes Obes Metab. Published 13 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →